ArticleFrontiers in oncology2025
Integrative modeling of FOXO-mediated autophagy in NSCLC: linking cGAS-STING signaling to IL-6 dynamics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Review
- miRNA-Mediated Signaling Networks in Non-Small Cell Lung Cancer: Linking Tumor Progression to Sarcopenia.International journal of molecular sciences · 2026Article
- Running out the clock: Circadian rhythm dysfunction in cognitive disease.International review of neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains the leading cause of cancer-related mortality worldwide, accounting for approximately 85% of lung cancer cases. Despite therapeutic advancements, the prognosis for advanced-stage NSCLC remains poor due to late diagnosis and high rates of therapeutic resistance. Recent studies have implicated the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in NSCLC progression, revealing its dual role in innate immune activation and autophagy induction. Concurrently, cGAS-STING activation triggers noncanonical autophagy. We proposed a systems biology framework integrating mathematical model and network biology to elucidate how forkhead box class O (FOXOs) FOXO1 and FOXO3a serve as critical regulators linking cGAS-STING signaling with interleukin-6 (IL-6) in promoting autophagy in NSCLC. Furthermore, sequence, phylogeny, structure, domain, and protein-protein interaction studies identified crucial amino acids and their functions in regulating cGAS-STING- FOXO1 and cGAS-STING-FOXO3a interactions. Our integrative model highlights the complex interplay between immune signaling, metabolic reprogramming, and autophagic regulation in NSCLC. Further findings offer mechanistic insights into the dual role of FOXO proteins in autophagy mediated cancer progression and present potential components for the development of personalized therapeutic strategies aimed at targeting the cGAS-STING-FOXO-autophagy axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.